Effect of 3.2 vs. 3.8% sodium citrate concentration on anti-Xa levels for patients on therapeutic low molecular weight heparin

Clinical and Laboratory Haematology

Volumn 25, Issue 5, 2003, Pages 317-319

  Payne, S ^a   Mackinnon, K ^b   Keeney, M ^b   Morrow, B ^b   Kovacs, M J ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Anti Xa levels; Low molecular weight heparin; Monitoring; Sodium citrate; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CITRATE SODIUM; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; BLOOD CLOTTING TEST; BLOOD SAMPLING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; INTERNATIONAL STANDARD UNIT; LUNG EMBOLISM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; STANDARDIZATION;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; CITRATES; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FIBRINOLYTIC AGENTS; HUMANS; VENOUS THROMBOSIS;

EID: 0141751601     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.2003.00542.x     Document Type: Article

References (17)

1. Abbate R., Goria M., Farsi A., Attanasio M. & Pepe G. (1998) Monitoring of low-molecular-weight heparins in cardiovascular disease. The American Journal of Cardiology 82, 33L-36L.
2. Adcock D.M., Kressin D.C. & Marlar R.A. (1997) Effect of 3.2% vs 3. 8% sodium citrate concentration on routine coagulation testing. American Journal of Clinical Pathology 107, 105-110.
3. Adcock D.M., Kressin D.C. & Marlar R.A. (1998) Minimum specimen volume requirements for routine coagulation testing dependence on citrate concentration. American Journal of Clinical Pathology 109, 595-599.
4. Alhenc-Gelas M., Jestin-Le G.C., Vitoux J.F., Kher A., Aiach M. & Fiessinger J.N. (1994) Adjusted versus fixed doses of the low molecular weight heparin Fragmin in the treatment of deep vein thrombosis. Thrombosis and Haemostasis 71, 698-702.
5. Boneu B. (1994) Low molecular weight heparin therapy: is monitoring needed? Thrombosis and Haemostasis 72, 330-334.
6. Danielson C.F.M., Davis K., Jones G., Benson J., Arney K. & Martin J. (1997) Effect of citrate concentration in specimen collection tubes on the international normalized ratio. Archives of Pathology and Laboratory Medicine 121, 956-959.
7. Duncan E.M., Casey C.R., Duncan B.M. & Lloyd J.V. (1994) Effect of concentration of trisodium citrate anticoagulant on calculation of the international normalised ratio and the international sensitivity index of thromboplastin. Thrombosis and Haemostasis 72, 84-88.
8. Fareed J., Hoppensteadt D., Jeske W., Clarizio R. & Walenga J.M. (1997) Low molecular weight herains: a developmental perspective. Expert Opinion on Investigational Drugs 6, 705-733.
9. Greaves M. (2002) Limitations of the laboratory monitoring of heparin therapy. Thrombosis and Haemostasis 87, 163-164.
10. Hirsh J. (1991) Heparin. New England Journal of Medicine 324, 1565-1574.
11. Hirsh J. & Levine M.N. (1992) Low molecular weight heparin. Blood 79, 1-17.
12. Howard P.A. (1997) Dalteparin: a low molecular weight heparin. Annals of Pharmacotherapy 31, 192-203.
13. Kitchen S., Iampietro R., Woolley A.M. & Preston F.E. (1999) Anti-Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thrombosis and Haemostasis 82, 1289-1293.
14. Kovacs M.J., Keeney M., MacKinnon K. & Boyle E. (1999) Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clinical and Laboratory Haematology 21, 55-60.
15. Levine M., Gent M., Hirsh J. et al. (1996). A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. New England Journal of Medicine 114, 677-681.
16. National Committee for Clinical Laboratory Standards (1998) Collection, transport, and processing of blood specimens for coagulation testing and general performance of coagulation assays, third edn, NCCLS document H21-A3, National Committee for Clinical Laboratory Standards, Wayne, PA.
17. Weitz J.I. (1997) Low-molecular-weight heparins. New England Journal of Medicine 337, 688-698.